MC4 receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-14. Numbers and descriptions here follow the published literature rather than marketing material.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
Trichilia catigua is a flowering plant species in the genus Trichilia. The species is used in folk medicine and shamanism in the aphrodisiac and stimulant catuaba. Cinchonain-Ib is a flavonolignan found in the bark of T. catigua. Catuaba from Trichilia catigua was found to increase the release of Serotonin as well as Dopamine in rats. Additionally, Trichilia catigua was shown to have neuroprotective effects in rats.
Semax (Russian: СЕМАКС), an abbreviation of "seven amino acids", (Russian: СЕМь АминоКиСлот, romanized: Sem aminokislot) is a medication which is used in Eastern Europe for the treatment of a broad range of conditions like brain trauma but predominantly for its claimed nootropic, neuroprotective, and neurorestorative effects. The mechanism of action of Semax is unknown. It might interact with certain melanocortin receptors or inhibit enkephalinase enzymes. Chemically, Semax is a peptide and a synthetic analogue of a fragment of adrenocorticotropic hormone (ACTH). Semax was first described in scientific literature in 1991. Although used as a prescription drug in Russia, Semax has not been evaluated, approved for use, or marketed in most other countries. The drug is widely sold by online vendors and used as a purported nootropic (cognitive enhancer).
genetic redundancy The redundant encoding of two or more distinct gene products that ultimately perform the same biochemical function. Mutations in one of these genes may have a smaller effect on fitness than might be expected, since the redundant genes often compensate for any loss of function and obviate any gain of function.
The earliest known reference to morphine can be traced back to Theophrastus in the 3rd century BC, however, possible references to morphine may go as far back as 2100 BC as Sumerian clay tablets which records lists of medical prescriptions including opium-based cures. An opium-based elixir has been ascribed to alchemists of Byzantine times, but the specific formula was lost during the Ottoman conquest of Constantinople (Istanbul). Around 1522, Paracelsus made reference to an opium-based elixir that he called laudanum from the Latin word laudāre, meaning "to praise". He described it as a potent painkiller but recommended that it be used sparingly. The recipe given differs substantially from that of modern-day laudanum. Morphine was discovered as the first active alkaloid extracted from the opium poppy plant in December 1804 in Paderborn by German pharmacist Friedrich Sertürner. Sertürner noticed the compound induced drowsiness in rats and stray dogs and he reported his findings in 1805. In 1817, Sertürner reported experiments in which he administered morphine to himself, three young boys, three dogs, and a mouse; all four people almost died. Sertürner originally named the substance morphium after the Greek god of dreams, Morpheus, as it has a tendency to cause sleep. Sertürner's morphium was six times stronger than opium. He hypothesized that, because lower doses of the drug were needed, it would be less addictive.
Postoperative wounds are those wounds acquired during surgical procedures. Postoperative wound healing occurs after surgery and normally follows distinct bodily reactions: the inflammatory response, the proliferation of cells and tissues that initiate healing, and the final remodeling. Postoperative wounds are different from other wounds in that they are anticipated and treatment is usually standardized depending on the type of surgery performed. Since the wounds are 'predicted' actions can be taken beforehand and after surgery that can reduce complications and promote healing.
Sources: en.wikipedia.org
Ribosomal DNA (rDNA) is more vulnerable to DNA damage than DNA elsewhere in the genome such that rDNA instability can lead to cellular senescence, and thus to SASP The high-mobility group proteins (HMGA) can induce senescence and SASP in a p53-dependent manner. Activation of the retrotransposon LINE1 can result in cytosolic DNA that activates the cGAS–STING cytosolic DNA sensing pathway upregulating SASP by induction of interferon type I. cGAS is essential for induction of cellular senescence by DNA damage. SASP secretion can also be initiated by the microRNAs miR-146 a/b. Senescent cells release mitochondrial double-stranded RNA (mt-dsRNA) into the cytosol driving the SASP via RIGI/MDA5/MAVS/MFN1. Moreover, senescent cells are hypersensitive to mt-dsRNA-driven inflammation due to reduced levels of PNPT1 and ADAR1.
== Presence == In cephalochordates (lancelets), the notochord persists throughout life as the main structural support of the body. In tunicates, the notochord is present only in the larval stage, becoming completely absent in the adult animal, and the notochord is not vacuolated. In all vertebrates other than the hagfish, the notochord is present only during early embryonic development and is later replaced by the bony and/or cartilaginous vertebral column, with its original structure being integrated into the intervertebral discs as the nucleus pulposus.
food and dietary supplement labeling purposes, the amount in a serving is expressed as a "percent of daily value" (%DV). For vitamin B12 labeling purposes, 100% of the daily value was 6.0 μg, but on 27 May 2016, it was revised downward to 2.4 μg (see Reference Daily Intake). Compliance with the updated labeling regulations was required by 1 January 2020 for manufacturers with US$10 million or more in annual food sales, and by 1 January 2021 for manufacturers with lower volume food sales.
=== Acting and filmmaking === Samberg majored in experimental film. He became an online star and made his own comedy videos with his friends Akiva Schaffer and Jorma Taccone. When YouTube was created in 2005, the streaming of their videos became much more widespread. Samberg became a featured player on Saturday Night Live in part because of the work he had done on his sketch comedy website TheLonelyIsland.com, which helped him land an agent and eventually get hired at Saturday Night Live. Prior to joining its cast, Samberg was (and remains) a member of the comedy troupe the Lonely Island, along with Taccone and Schaffer. The trio began writing for Saturday Night Live in 2005 and released their debut album Incredibad in 2009. Samberg appeared in numerous theatrical films, commercials, music videos, and hosted special events, including the 2009 MTV Movie Awards. In 2012, Samberg delivered the Class Day speech at Harvard University, and he starred with Adam Sandler in That's My Boy. The same year, he starred with Adam Sandler again in Hotel Transylvania as Jonathan, a role he reprised for its sequels Hotel Transylvania 2, Hotel Transylvania 3: Summer Vacation and Hotel Transylvania: Transformania. In September 2012, Samberg played Cuckoo in the BAFTA nominated BBC Three series Cuckoo; and, in 2013, he landed the role of Detective Jake Peralta in Fox's (later NBC's) police sitcom Brooklyn Nine-Nine, which first aired on September 17 of the same year. Samberg won the Golden Globe Award for Best Actor – Television Series Musical or Comedy in 2014 for his role as Peralta.
==== Declined ==== Grant Moody, Bexar County commissioner from the 3rd precinct Kyle Sinclair, former vice chair of the Bexar County Republican Party, nominee for the 20th district in 2022, and candidate for the 28th district in 2024 (ran in the 21st district) Marc Whyte, San Antonio city councilor from the 10th district (2023–present) and candidate for Texas's 121st House of Representatives district in 2018 (endorsed Lujan)
Sources: en.wikipedia.org
On 2 January, Lula revoked a bill made during the Bolsonaro government, which created schools exclusively for persons with disabilities, with the revocation of this law, these students are now able to study in the same schools as other students, while keeping the need for special treatment in some severe cases. On 11 January, Lula signed in a bill called the "National Digital Education Policy", which deals with expanding access to digital education in the country. Another measure taken by the government was the increase in the amount for research grants, Lula later stated that "this government is forbidden to treat [as] wasted money what goes to education, money that goes to scholarships, money that goes to healthcare and research". On 10 March, Lula announced a readjustment in the values of the school meals of public schools, after having been frozen for more than five years. The increase is 39% and the value is 5.5 billion per year. In April, after severe pressure from Student and Teacher unions, the Ministry of Education announced the temporary suspension of the "New High School" programme, however, there was no revocation of the project, and it would later be reinstated in August by Minister of Education Camilo Santana, although with some changes. Also in April, Lula announced that the government would invest over 6 billion in a project to restart the construction of several works in the education area, such as public schools.
== Career == Bigbie attended Ball State University. In 1998, he played collegiate summer baseball with the Wareham Gatemen of the Cape Cod Baseball League. Bigbie was drafted by the Baltimore Orioles in the 1st round (21st pick overall) of the 1999 Major League Baseball amateur draft and played over four years (2001–2005) for the Orioles before being traded during the 2005 season to the Colorado Rockies. Bigbie played the remainder of 2005 season for the Rockies. On December 8, 2005, the Rockies traded him and Aaron Miles to the St. Louis Cardinals for pitcher Ray King. On February 2, 2007, he signed a minor league deal with the Los Angeles Dodgers. Bigbie exercised a free agent option in his contract on June 1, 2007, and on June 11 signed a minor league contract with the Braves. During his six-year career, he posted a .268 batting average, hitting 31 home runs and amassing 322 hits in 375 games. Bigbie is an average fielder, but has an above-average arm. He batted .240 in 2006 with the Cardinals, also posting only 1 RBI, in 17 games. In December 2007, it was announced that he had agreed to a deal to play for the Yokohama Bay Stars of the Nippon Professional Baseball (NPB). Bigbie made a comeback for the 2010 season, playing for the Edmonton Capitals of the Golden Baseball League. Bigbie was named the DH for Baseball America's 2010 All-Independent Leagues Team.
After 10 years without any new releases to the series, Gearbox acquired the rights to the Homeworld series from THQ in 2013. Shortly after that the Homeworld Remastered Collection was released in 2015, containing updated High-Definition versions of Homeworld and Homeworld 2 compatible with modern Windows and Mac OS X systems. In September 2013, Gearbox announced a partnership with Blackbird Interactive and licensing the Homeworld-IP for its then-named Hardware: Shipbreakers game. This game later became Homeworld: Deserts of Kharak and was released on January 20, 2016 as a prequel to the original Homeworld game of 1999. On August 30, 2019, Gearbox announced Homeworld 3 which was developed by Blackbird Interactive. The game's development was at least partially funded through a crowdfunding campaign on the Fig platform, and was released May 13, 2024.
==== Intracrine actions of PTHrP in cardiac cells ==== PTHrP exists in multiple isoforms, with some retained intracellularly rather than secreted. In cardiac myocytes and vascular smooth muscle cells, intracrine PTHrP is known to localize within the nucleus, where it regulates gene transcription, modulates cell proliferation, and affects intracellular calcium handling. One of the hallmark intracrine functions of PTHrP is its ability to influence angiogenesis. Studies have shown that nuclear PTHrP interacts with ribosomal DNA to upregulate genes involved in endothelial cell proliferation and vascular development. This action mirrors other intracrine factors, such as VEGF, which also regulate angiogenesis through nuclear localization.
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.